Ebert Lisa M, Tan Lih Y, Johan M Zahied, Min Kay Khine Myo, Cockshell Michaelia P, Parham Kate A, Betterman Kelly L, Szeto Paceman, Boyle Samantha, Silva Lokugan, Peng Angela, Zhang YouFang, Ruszkiewicz Andrew, Zannettino Andrew C W, Gronthos Stan, Koblar Simon, Harvey Natasha L, Lopez Angel F, Shackleton Mark, Bonder Claudine S
Centre for Cancer Biology, University of South Australia and SA Pathology, PO Box 14, Rundle Mall, Adelaide, SA, 5000, Australia.
Cancer Development and Treatment Laboratory, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Angiogenesis. 2016 Oct;19(4):463-86. doi: 10.1007/s10456-016-9520-y. Epub 2016 Jun 23.
Desmogleins (DSG) are a family of cadherin adhesion proteins that were first identified in desmosomes and provide cardiomyocytes and epithelial cells with the junctional stability to tolerate mechanical stress. However, one member of this family, DSG2, is emerging as a protein with additional biological functions on a broader range of cells. Here we reveal that DSG2 is expressed by non-desmosome-forming human endothelial progenitor cells as well as their mature counterparts [endothelial cells (ECs)] in human tissue from healthy individuals and cancer patients. Analysis of normal blood and bone marrow showed that DSG2 is also expressed by CD34(+)CD45(dim) hematopoietic progenitor cells. An inability to detect other desmosomal components, i.e., DSG1, DSG3 and desmocollin (DSC)2/3, on these cells supports a solitary role for DSG2 outside of desmosomes. Functionally, we show that CD34(+)CD45(dim)DSG2(+) progenitor cells are multi-potent and pro-angiogenic in vitro. Using a 'knockout-first' approach, we generated a Dsg2 loss-of-function strain of mice (Dsg2 (lo/lo)) and observed that, in response to reduced levels of Dsg2: (i) CD31(+) ECs in the pancreas are hypertrophic and exhibit altered morphology, (ii) bone marrow-derived endothelial colony formation is impaired, (iii) ex vivo vascular sprouting from aortic rings is reduced, and (iv) vessel formation in vitro and in vivo is attenuated. Finally, knockdown of DSG2 in a human bone marrow EC line reveals a reduction in an in vitro angiogenesis assay as well as relocalisation of actin and VE-cadherin away from the cell junctions, reduced cell-cell adhesion and increased invasive properties by these cells. In summary, we have identified DSG2 expression in distinct progenitor cell subpopulations and show that, independent from its classical function as a component of desmosomes, this cadherin also plays a critical role in the vasculature.
桥粒芯糖蛋白(DSG)是一类钙黏蛋白黏附蛋白,最初在桥粒中被鉴定出来,为心肌细胞和上皮细胞提供连接稳定性以耐受机械应力。然而,该家族的一个成员DSG2,正逐渐成为一种在更广泛细胞类型中具有额外生物学功能的蛋白质。在此我们揭示,在健康个体和癌症患者的人体组织中,非形成桥粒的人类内皮祖细胞及其成熟对应细胞(内皮细胞,ECs)均表达DSG2。对正常血液和骨髓的分析表明,CD34(+)CD45(dim)造血祖细胞也表达DSG2。在这些细胞上无法检测到其他桥粒成分,即DSG1、DSG3和桥粒胶蛋白(DSC)2/3,这支持了DSG2在桥粒之外的单独作用。在功能上,我们表明CD34(+)CD45(dim)DSG2(+)祖细胞在体外具有多能性且促血管生成。使用“敲除优先”方法,我们构建了Dsg2功能缺失的小鼠品系(Dsg2 (lo/lo)),并观察到,响应于Dsg2水平降低:(i)胰腺中的CD31(+) ECs肥大且形态改变,(ii)骨髓来源的内皮集落形成受损,(iii)主动脉环的体外血管发芽减少,以及(iv)体外和体内的血管形成减弱。最后,在人骨髓EC系中敲低DSG2显示,体外血管生成试验中血管生成减少,肌动蛋白和VE-钙黏蛋白从细胞连接处重新定位,细胞间黏附减少,且这些细胞的侵袭特性增加。总之,我们在不同的祖细胞亚群中鉴定出了DSG2的表达,并表明,独立于其作为桥粒成分的经典功能之外,这种钙黏蛋白在脉管系统中也起着关键作用。